MEETINGS

Thursday, February 12

RESIDENT LECTURES

PGY 1—4 and Child and Adolescent Psychiatry
Residents: Please see weekly didactic notice emails from the Education Office for scheduled topics and presenters.

Friday, February 13

THIRD YEAR MEDICAL STUDENTS

8-10 AM Psychopharmacology—Glen Catalano, MD
10-12 noon Mood/Substance Abuse Case Discussion—Jennifer White, MD

IN THE KNOW!!!

Happy Birthday to
Helena Hernandez-Cuervo/Feb. 9,
Jose Valdes/Feb. 13!!!

GRAND ROUNDS

Thursday, February 12, 2015 at 12 noon–1 PM
Second Floor Psychiatry Conference Room #232

TIME EFFICIENT CLINICAL TEACHING AND FEEDBACK FOR BUSY PRACTITIONERS

presented by FRAZIER STEVENSON, MD
Associate Dean for Undergraduate Medical Education
University of South Florida College of Medicine

Continued on page 2
IN THE KNOW!!!

2015 FACULTY & STAFF CAMPAIGN

The Morsani College of Medicine’s faculty and staff make up about one sixth of ALL of the faculty and staff at USF, making it impossible for the University to reach its goal without our help. We are currently at 27 percent participation, and our goal is to reach 100 percent by the end of June 2015. It’s important to remember that every dollar does make a difference. Please consider giving back to our department, and see firsthand the impact this campaign has on our day-to-day experiences at USF Health.

Below are our priority funds identified by the leadership:

250061 – Child Development Center Operating Fund
430010 – Psychiatry Operating Fund
256048 – Center for Infant & Child Development
256072 – Daniel Sprehe Memorial, USF Forensic Psychiatry
256260 – Robert Roskamp Chair in Biological Psychiatry

You can make a gift to any fund within the USF System and your gift will count towards our department’s participation goal. To make your gift today, please click the link below, or for a paper contribution form, contact Paul DeCosta.

www.USF.edu/FSCC

Continued on page 3
Now Enrolling – Mild Alzheimer’s disease

This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits. Please call Kathy at (813)974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

The purpose of this research study is to know if the antibiotic azithromycin improves symptom severity in children with sudden and severe onset obsessive compulsive symptoms known as PANS, Pediatric Acute Onset Neuropsychiatric Syndrome, and PANDAS, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus. This study seeks to compare the effects of placebo vs. azithromycin on symptom severity as well as to assess immune risk factors in children with PANDAS/PANS. Your child is being asked to take part in this research study because he/she may meet criteria for PANS/PANDAS and has a current episode of Obsessive-Compulsive Disorder (OCD) symptoms of less than or equal to 6 months that has been associated with an infection. Children ages 4-14 years old who are not currently taking prophylactic antibiotics or undergoing cognitive behavioral therapy (CBT) are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (AZD5213) for Adolescents with Tourette’s Disorder

The purpose of this research study is to assess the safety, tolerability, and effectiveness of an investigational medication (AZD5213) in adolescents with Tourette’s disorder (TD). AZD5213 is a novel histamine H3 receptor inverse agonist that shows promise for the potential treatment of a variety of indications, including TD. This is a multicenter, randomized, two-part study of AZD5213 in adolescents (ages 12-17 years) with TD. In Part 1 of the study, following an up to 21-day screening period, eligible subjects will receive a single small dose of AZD5213 in-clinic. In Part 2 of the study, each treatment (AZD5213 or placebo) will be administered in two 3-week periods (six treatment periods, total). Each treatment will be received in one of Periods 1-3, and again in one of Periods 4-6. Visits will occur weekly during Part 2 of the study. Some visits will be in-clinic; while other visits will be performed by telephone. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Continued on page 4
Investigational Medication (Bitopertin) for Adults with OCD

The purpose of this research study is to evaluate an investigational medication (bitopertin) for adults with OCD, and determine if patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD. To pre-qualify for this study, patients must be between the ages of 18 and 65 years, currently taking medication for OCD, and continue to have symptoms of OCD while on medication. Additional eligibility requirements will be discussed with all potential participants prior to enrollment. Reimbursement for travel may also be provided. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Pediatric OCD D-Cycloserine & Cognitive Behavioral Therapy (CBT) Research Study

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

Continued on page 5
RESEARCH HAPPENINGS!

Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

The purpose of this research study is to assess the efficacy of a form of Cognitive Behavioral Therapy (CBT), called Stepped Care CBT, that requires fewer therapy visits and utilizes family members as active components in treatment. Children and families who are interested must complete an initial assessment to determine eligibility.

Eligible participants must be between 8 and 17 years of age and have a primary diagnosis of Obsessive Compulsive Disorder. Once eligibility is determined, participants will be randomly assigned to receive Stepped Care CBT or standard CBT. Those receiving Stepped Care CBT begin treatment in “Step One” which includes 3 sessions with a therapist over the course of 6 weeks while being coached through a take-home workbook. If after 6 weeks it is determined by the research team that insufficient progress has been made, participants progress to “Step Two” which includes 9 additional therapy sessions over 9 weeks. Those receiving standard CBT will receive weekly therapy sessions for 12 weeks. Please contact Brittney Dane at (727) 767-7427 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

Habit Reversal Training for Children and Adolescents with Trichotillomania: A Controlled Trial

The purpose of this research study is to further investigate how well Habit Reversal Training (HRT) works to reduce hair-pulling symptoms in children and adolescents with Trichotillomania. Trichotillomania (TTM) is a condition that involves strong urges to pull out one’s own hair. Children and families who are interested must complete an initial assessment to determine eligibility. Eligible participants must be between years of age 7 and 17 and be diagnosed with TTM. All children will have the option to receive 8 weekly HRT sessions that are up to 60-minutes each. Half of all children will be chosen at random to receive these sessions immediately and the remaining half will receive the sessions after eight weeks.

These sessions will focus on developing skills for managing TTM and decrease hair pulling. For more information please call (727) 767-8230 and ask for Amanda Collier.

Principal Investigators: Adam Lewin, PhD, ABPP and Omar Rahman, PhD